|
gptkbp:instanceOf
|
gptkb:antibiotic
cephalosporin
|
|
gptkbp:administeredBy
|
adults
children
neonates (with caution)
|
|
gptkbp:approvalYear
|
1982
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
J01DD04
|
|
gptkbp:brand
|
gptkb:Rocephin
|
|
gptkbp:CASNumber
|
73384-59-5
|
|
gptkbp:chemicalClass
|
cephalosporin
|
|
gptkbp:chemicalFormula
|
beta-lactam ring
|
|
gptkbp:concerns
|
extended-spectrum beta-lactamases
|
|
gptkbp:contraindication
|
allergy to cephalosporins
neonates with hyperbilirubinemia
|
|
gptkbp:discoveredBy
|
gptkb:Hoffmann-La_Roche
|
|
gptkbp:eliminationHalfLife
|
6-9 hours
|
|
gptkbp:excretion
|
urine
bile
|
|
gptkbp:foundIn
|
gptkb:WHO_Model_List_of_Essential_Medicines
|
|
gptkbp:hasMolecularFormula
|
C18H18N8O7S3
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ceftriaxone
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits bacterial cell wall synthesis
|
|
gptkbp:metabolism
|
not significantly metabolized
|
|
gptkbp:pregnancyCategory
|
B (US)
B1 (Australia)
|
|
gptkbp:proteinBinding
|
85-95%
|
|
gptkbp:riskFactor
|
gptkb:Clostridioides_difficile_infection
superinfection
|
|
gptkbp:routeOfAdministration
|
intramuscular
intravenous
|
|
gptkbp:sideEffect
|
diarrhea
rash
allergic reactions
pain at injection site
gallbladder sludge
|
|
gptkbp:spectrumOfActivity
|
broad-spectrum
|
|
gptkbp:synonym
|
gptkb:Ceftriaxonum
gptkb:Rocephin
|
|
gptkbp:usedFor
|
gptkb:pneumonia
meningitis
sepsis
urinary tract infections
gonorrhea
bacterial infections
intra-abdominal infections
skin and soft tissue infections
bone and joint infections
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
true
|
|
gptkbp:bfsParent
|
gptkb:Typhoid_Fever
|
|
gptkbp:bfsLayer
|
5
|